Eos Energy stock falls after Fuzzy Panda issues short report
Euda Health Holdings Ltd (NASDAQ:EUDA) announced a change to its board of directors, according to a press release statement based on a recent SEC filing. On October 23, independent director Wong Kong Yew resigned from the board, as well as from his positions as Chairman of the Compensation Committee and member of the Audit and Nomination Committees. The company stated that Prof. Wong’s resignation was not due to any disagreement or dispute with Euda or its board regarding company operations, policies, or practices.
Following the resignation, the Nominating Committee nominated Huang Bo to serve as an independent director. The board determined that Mr. Huang meets the independence requirements under applicable Nasdaq rules and Rule 10A-3 of the United States Securities Exchange Act of 1934. Mr. Huang was appointed as independent director, Chairman of the Compensation Committee, and member of both the Audit and Nomination Committees, effective October 24.
Mr. Huang is the General Manager of Shenzhen Key Lock Biotechnology Co., Ltd., a company whose sole owner also owns Guangdong Key Lock Health Management Co., Ltd., a business partner of Euda Health Holdings. Guangdong Key Lock Health Management provides Euda with rights to sell and distribute certain third-party-developed stem cell therapies in Singapore and Malaysia, and cell immunotherapies in Malaysia. The board considered Mr. Huang’s relationship with these companies and stated that his position would not interfere with his independent judgment as a director.
Mr. Huang’s prior roles include City Manager at Shenzhen Kewei Robotics Technology Co., Ltd. from March 2020 to June 2024, Project Manager at Shenzhen Xixi Network Technology Co., Ltd. from October 2016 to July 2019, and Shenzhen Market Operations Director at Magic Line Technology (Shenzhen) Co., Ltd., a NASDAQ-listed company, from March 2013 to September 2016. He holds a Bachelor’s Degree from Zhengzhou University of Technology, earned in July 2009.
The company reported that there are no arrangements or understandings with any person regarding Mr. Huang’s appointment, and no related-party transactions requiring disclosure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.